1639866-74-2

Upstream product

• 220286-47-5 3-Amino-5-hydroxymethylbenzoic acid methyl ester 
• 1639866-73-1 C₁₄H₁₉NO₅ 
• 1955-46-0 5-nitro-1,3-benzenedicarboxylic acid, monomethyl ester 
• 53732-08-4 3-hydroxymethyl-5-nitrobenzoic acid methyl ester 
• 18595-15-8 methyl 3-amino-5-methylbenzoate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1639866-75-3 methyl 3-[(tert-butoxycarbonyl)amino]-5-(3-(trimethylsilyl)prop-2-yn-1-yl)benzoate 

Relevant academic research and scientific papers

MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Preparation of new alkyne-modified ansamitocins by mutasynthesis

The preparation of alkyne-modified ansamitocins by mutasynthetic supplementation of Actinosynnema pretiosum mutants with alkyne-substituted aminobenzoic acids is described. This modification paved the way to introduce a thiol linker by Huisgen-type cycloaddition which can principally be utilized to create tumor targeting conjugates. In bioactivity tests, only those new ansamitocin derivatives showed strong antiproliferative activity that bear an ester side chain at C-3.